Grünenthal Overview

  • Year Founded
  • 1946

Year Founded

  • Status
  • Private

  • Employees
  • 4,122

Employees

  • Latest Deal Type
  • Debt Refin.

  • Financing Rounds
  • 20

  • Investments
  • 22

Grünenthal General Information

Description

Developer of a pharmaceutical company designed to improve pain management and related diseases. The company offers innovative treatments and advanced medical technologies, enabling patients worldwide to experience better health and enhanced quality of life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • Zieglerstraße 6
  • 52078 Aachen
  • Germany
+49 0241
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Corporate Office
  • Zieglerstraße 6
  • 52078 Aachen
  • Germany
+49 0241

Grünenthal Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Grünenthal Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Grünenthal‘s full profile, request access.

Request a free trial

Grünenthal Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a pharmaceutical company designed to improve pain management and related diseases. The company offers innov
Pharmaceuticals
Aachen, Germany
4,122 As of 2026

Raritan, NJ
 

Dublin, Ireland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Grünenthal Competitors (41)

One of Grünenthal’s 41 competitors is Johnson&Johnson Innovative Medicine, a Venture Capital-Backed company based in Raritan, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Johnson&Johnson Innovative Medicine Venture Capital-Backed Raritan, NJ
Amarin Corporation Corporation Dublin, Ireland
Acura Pharmaceuticals Formerly VC-backed Palatine, IL
Chiesi Farmaceutici Private Debt Financed Parma, Italy
Tris Pharma Private Debt Financed Monmouth Junction, NJ
You’re viewing 5 of 41 competitors. Get the full list »

Grünenthal Patents

Grünenthal Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026202313-A1 Aryloxyacetamides Pending 27-Mar-2025
WO-2026176034-A1 Topical capsaicin for treating sleep disturbance and/or neuropathic pain Pending 20-Feb-2025
US-20250368625-A1 Piperazines Pending 29-May-2024
AU-2025276960-A1 Piperazines which act as sstr4 modulators Pending 29-May-2024
WO-2025247982-A1 Piperazines which act as sstr4 modulators Pending 29-May-2024 C07D403/12
To view Grünenthal’s complete patent history, request access »

Grünenthal Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Grünenthal Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Grünenthal‘s full profile, request access.

Request a free trial

Grünenthal Investments & Acquisitions (22)

Grünenthal’s most recent deal was a Buyout/LBO with Stivarga for . The deal was made on 21-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Stivarga 21-Sep-2026 Buyout/LBO Pharmaceuticals
Grünenthal Meds 02-Mar-2026 Secondary Transaction - Private Other Pharmaceuticals and Biotechnology
Eli Lilly (Rights to Cialis in Mexico, Brazil and Colombia) 02-Jun-2025 Buyout/LBO Buildings and Property
Valinor Pharma 22-Jul-2024 Buyout/LBO Pharmaceuticals
Grünenthal Meds 02-Aug-2023 Joint Venture Other Pharmaceuticals and Biotechnology
You’re viewing 5 of 22 investments and acquisitions. Get the full list »

Grünenthal Exits (2)

Grünenthal’s most recent exit was on 01-Jan-1993 from Laboratorios Medicamentos Internacionales. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Laboratorios Medicamentos Internacionales 01-Jan-1993 Completed
Laboratorios Medicamentos Internacionales 01-Jan-1979 Corporate Completed
To view Grünenthal’s complete exits history, request access »

Grünenthal Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
Grt Us Holding Morristown, NJ 2018
Laboratorios Andromaco Santiago, Chile 1942
Valinor Pharma Chicago, IL

Grünenthal FAQs

  • When was Grünenthal founded?

    Grünenthal was founded in 1946.

  • Where is Grünenthal headquartered?

    Grünenthal is headquartered in Aachen, Germany.

  • What is the size of Grünenthal?

    Grünenthal has 4,122 total employees.

  • What industry is Grünenthal in?

    Grünenthal’s primary industry is Pharmaceuticals.

  • Is Grünenthal a private or public company?

    Grünenthal is a Private company.

  • What is Grünenthal’s current revenue?

    The current revenue for Grünenthal is .

  • How much funding has Grünenthal raised over time?

    Grünenthal has raised $8.2B.

  • Who are Grünenthal’s investors?

    NovaQuest Capital Management has invested in Grünenthal.

  • Who are Grünenthal’s competitors?

    Johnson&Johnson Innovative Medicine, Amarin Corporation, Acura Pharmaceuticals, Chiesi Farmaceutici, and Tris Pharma are some of the 41 competitors of Grünenthal.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process